Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
Unbranded patient piece highlighting certain comorbidities
-
Hi there,
Could we make an unbranded patient piece with an overall focus on Disease A (e.g., what it is, what causes it, all available management options [both pharma and non-pharma]) that includes a section on co-morbidities associated with Disease A? In this section, could we highlight (and by "highlight" I mean "provide more information on") one of the more common co-morbidities without highlighting the others?
Thank you!
-
Hi @kshulist
Assuming that the highlighting of select co-morbidities did not favour one class of products over another and that the co-morbidities were not tied back to any off-label therapeutic implications for products, it could theoretically be done in the context described.
-
@jennifer-carroll Hi Jen,
Thanks so much for your answer! I just wanted to clarify what you meant when you said "that the co-morbidities were not tied back to any off-label therapeutic implications for products". What does that mean for including certain drug classes in the "pharma treatment section" of our piece? (Some drugs within a class may be indicated for the co-morbidity and some may not - is it still okay to mention the whole class in our pharma treatments section?)
-
Hi @kshulist
In general, you want to apply the following litmus test:
Would a user be able to identify the sponsor?
Would competitors be equally as likely to sponsor the distribution of the piece?You can assume that if you are treating a condition that has three drug classes which treat the condition, and one of them has an indication which includes a comorbidity that the other two do not, focusing on that comorbidity, would not be acceptable.
-
@jennifer-carroll Thanks for clarifying! I understand now
